TNXP Tonix Pharmaceuticals | $0.17
| 2/28/2024 | Initiated by | Dawson James | - | Buy | $3.00 | Low | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 2/28/2024 |
DARE Daré Bioscience | $0.43 -8.5% | 1/30/2024 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 1/30/2024 |
BYRN Byrna Technologies | $12.11 -2.9% | 9/27/2023 | Downgraded by | Dawson James | - | Buy -> Neutral | | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/27/2023 |
HILS Hillstream BioPharma | $4.49 -7.2% | 7/17/2023 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Hillstream BioPharma (NASDAQ:HILS) on 7/17/2023 |
BYRN Byrna Technologies | $12.11 -2.9% | 7/12/2023 | Target Lowered by | Dawson James | - | | $9.50 -> $7.25 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 7/12/2023 |
TOON Kartoon Studios | $1.03 -1.9% | 7/11/2023 | Target Lowered by | Dawson James | - | | $12.50 -> $10.00 | Low | View details for Dawson James rating of Kartoon Studios (NASDAQ:TOON) on 7/11/2023 |
1k a day while computer does all work? (Ad) Does your computer make you 1k a day?
If not… you don’t need a new computer…
You need to learn how to set it up so it makes you money.
Click here to register. |
NRXP NRx Pharmaceuticals | $3.68 -3.4% | 3/17/2023 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of NRx Pharmaceuticals (NASDAQ:NRXP) on 3/17/2023 |
HILS Hillstream BioPharma | $4.49 -7.2% | 2/22/2023 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of Hillstream BioPharma (NASDAQ:HILS) on 2/22/2023 |
SMSI Smith Micro Software | $2.18 -1.4% | 2/28/2023 | Target Lowered by | Dawson James | - | | $66.40 -> $28.00 | Low | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 2/28/2023 |
ZOM Zomedica | $0.16
| 1/6/2023 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Zomedica (NYSEAMERICAN:ZOM) on 1/6/2023 |
BCDA BioCardia | $5.20 +0.6% | 11/11/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 11/11/2022 |
CHEK Check-Cap | $2.29 -0.4% | 9/15/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 9/15/2022 |
BYRN Byrna Technologies | $12.11 -2.9% | 9/8/2022 | Target Lowered by | Dawson James | - | | $12.00 -> $9.50 | Low | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 9/8/2022 |
PRPH ProPhase Labs | $4.94 -4.1% | 7/21/2022 | Downgraded by | Dawson James | - | Neutral -> Sell | | Low | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 7/21/2022 |
DYAI Dyadic International | $2.27 +5.6% | 7/18/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 7/18/2022 |
KTRA Kintara Therapeutics | $0.32 +14.4% | 5/16/2022 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of Kintara Therapeutics (NASDAQ:KTRA) on 5/16/2022 |
BYRN Byrna Technologies | $12.11 -2.9% | 4/26/2022 | Initiated by | Dawson James | - | Buy | $12.00 | High | View details for Dawson James rating of Byrna Technologies (NASDAQ:BYRN) on 4/26/2022 |
LCTX Lineage Cell Therapeutics | $0.99 +6.5% | 3/11/2022 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 3/11/2022 |
SMSI Smith Micro Software | $2.18 -1.4% | 3/11/2022 | Target Lowered by | Dawson James | - | Buy | $91.20 -> $66.40 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 3/11/2022 |
PFIE Profire Energy | $1.57 +1.3% | 3/9/2022 | Target Raised by | Dawson James | - | | $1.65 -> $2.00 | Low | View details for Dawson James rating of Profire Energy (NASDAQ:PFIE) on 3/9/2022 |
KNWN Know Labs | $0.58 -4.9% | 2/8/2022 | Initiated by | Dawson James | - | Buy | $7.00 | High | View details for Dawson James rating of Know Labs (OTCMKTS:KNWN) on 2/8/2022 |
CHEK Check-Cap | $2.29 -0.4% | 2/7/2022 | Upgraded by | Dawson James | - | Neutral -> Buy | | High | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 2/7/2022 |
BCLI Brainstorm Cell Therapeutics | $0.52 -1.9% | 12/22/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Neutral | | Medium | View details for Dawson James rating of Brainstorm Cell Therapeutics (NASDAQ:BCLI) on 12/22/2021 |
VUZI Vuzix | $1.44 -7.7% | 12/21/2021 | Initiated by | Dawson James | - | Buy | $15.00 | Medium | View details for Dawson James rating of Vuzix (NASDAQ:VUZI) on 12/21/2021 |
PRPH ProPhase Labs | $4.94 -4.1% | 10/13/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 10/13/2021 |
PFIE Profire Energy | $1.57 +1.3% | 8/5/2021 | Initiated by | Dawson James | Analyst James McIlree | Buy | $1.65 | High | View details for Dawson James rating of Profire Energy (NASDAQ:PFIE) on 8/5/2021 |
SMSI Smith Micro Software | $2.18 -1.4% | 8/5/2021 | Initiated by | Dawson James | - | Buy | $88.80 | High | View details for Dawson James rating of Smith Micro Software (NASDAQ:SMSI) on 8/5/2021 |
AVXL Anavex Life Sciences | $4.14 +6.4% | 6/21/2021 | Target Raised by | Dawson James | - | Buy | $19.00 -> $35.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/21/2021 |
BCDA BioCardia | $5.20 +0.6% | 4/22/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Medium | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/22/2021 |
BCDA BioCardia | $5.20 +0.6% | 4/16/2021 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | High | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 4/16/2021 |
CHEK Check-Cap | $2.29 -0.4% | 3/17/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | $40.00 | Low | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 3/17/2021 |
CTXR Citius Pharmaceuticals | $0.66 +4.8% | 2/25/2021 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | $6.00 | Low | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 2/25/2021 |
FBIO Fortress Biotech | $1.83 +0.5% | 2/17/2021 | Target Raised by | Dawson James | - | Buy | $240.00 -> $315.00 | Low | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 2/17/2021 |
PRPH ProPhase Labs | $4.94 -4.1% | 1/20/2021 | Initiated by | Dawson James | - | Buy | $25.00 | High | View details for Dawson James rating of ProPhase Labs (NASDAQ:PRPH) on 1/20/2021 |
LCTX Lineage Cell Therapeutics | $0.99 +6.5% | 10/12/2020 | Reiterated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) on 10/12/2020 |
CTXR Citius Pharmaceuticals | $0.66 +4.8% | 9/17/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Low | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/17/2020 |
DARE Daré Bioscience | $0.43 -8.5% | 7/12/2020 | Reiterated by | Dawson James | - | Buy | $3.00 | High | View details for Dawson James rating of Daré Bioscience (NASDAQ:DARE) on 7/12/2020 |
AVXL Anavex Life Sciences | $4.14 +6.4% | 6/8/2020 | Reiterated by | Dawson James | - | Buy | $16.00 | Medium | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 6/8/2020 |
CTSO Cytosorbents | $0.88 -2.2% | 3/9/2020 | Reiterated by | Dawson James | - | Buy | $15.00 -> $17.00 | High | View details for Dawson James rating of Cytosorbents (NASDAQ:CTSO) on 3/9/2020 |
DYAI Dyadic International | $2.27 +5.6% | 2/26/2020 | Reiterated by | Dawson James | Analyst Jason Kolbert | Buy | | High | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 2/26/2020 |
Get out of dollars—get into America’s new money instead (Ad) Is America's New Money right for you?
I can't say... but I do know it's 100% legal and available to everyone... although precious few know much about it. Everything you need to know is posted on our website here. |
IMAC IMAC | $2.87 -2.0% | 1/14/2020 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | | Low | View details for Dawson James rating of IMAC (NASDAQ:IMAC) on 1/14/2020 |
MESO Mesoblast | $7.55 -5.9% | 12/19/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $28.00 | Low | View details for Dawson James rating of Mesoblast (NASDAQ:MESO) on 12/19/2019 |
CHEK Check-Cap | $2.29 -0.4% | 12/5/2019 | Initiated by | Dawson James | - | Buy | $80.00 | Low | View details for Dawson James rating of Check-Cap (NASDAQ:CHEK) on 12/5/2019 |
DYAI Dyadic International | $2.27 +5.6% | 10/16/2019 | Initiated by | Dawson James | - | Buy | $14.00 | Low | View details for Dawson James rating of Dyadic International (NASDAQ:DYAI) on 10/16/2019 |
BCDA BioCardia | $5.20 +0.6% | 9/17/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $360.00 | Low | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
BCDA BioCardia | $5.20 +0.6% | 9/17/2019 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | Medium | View details for Dawson James rating of BioCardia (NASDAQ:BCDA) on 9/17/2019 |
CTXR Citius Pharmaceuticals | $0.66 +4.8% | 9/6/2019 | Initiated by | Dawson James | Analyst Jason Kolbert | Buy | $7.00 | N/A | View details for Dawson James rating of Citius Pharmaceuticals (NASDAQ:CTXR) on 9/6/2019 |
FBIO Fortress Biotech | $1.83 +0.5% | 8/26/2019 | Initiated by | Dawson James | - | Buy | $285.00 | High | View details for Dawson James rating of Fortress Biotech (NASDAQ:FBIO) on 8/26/2019 |
ADMA ADMA Biologics | $9.48 +0.9% | 8/12/2019 | Downgraded by | Dawson James | Analyst J. Kolbert | Buy -> Neutral | $4.00 | High | View details for Dawson James rating of ADMA Biologics (NASDAQ:ADMA) on 8/12/2019 |
AVXL Anavex Life Sciences | $4.14 +6.4% | 7/24/2019 | Initiated by | Dawson James | Analyst J. Kolbert | Buy | $16.00 | Low | View details for Dawson James rating of Anavex Life Sciences (NASDAQ:AVXL) on 7/24/2019 |
KTRA Kintara Therapeutics | $0.32 +14.4% | 7/11/2019 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | High | View details for Dawson James rating of Kintara Therapeutics (NASDAQ:KTRA) on 7/11/2019 |
INTT inTEST | $9.75
| 12/28/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of inTEST (NYSE:INTT) on 12/28/2018 |
ORGS Orgenesis | $0.49 -2.0% | 12/20/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Orgenesis (NASDAQ:ORGS) on 12/20/2018 |
SSNT SilverSun Technologies | $19.50 +0.3% | 12/19/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of SilverSun Technologies (NASDAQ:SSNT) on 12/19/2018 |
BCLI Brainstorm Cell Therapeutics | $0.52 -1.9% | 12/18/2018 | Reiterated by | Dawson James | Analyst J. Kolbert | Buy | | High | View details for Dawson James rating of Brainstorm Cell Therapeutics (NASDAQ:BCLI) on 12/18/2018 |
ORGS Orgenesis | $0.49 -2.0% | 12/20/2018 | Initiated by | Dawson James | - | Buy -> Buy | | Medium | View details for Dawson James rating of Orgenesis (NASDAQ:ORGS) on 12/20/2018 |
GVP GSE Systems | $4.16 +19.5% | 12/18/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of GSE Systems (NASDAQ:GVP) on 12/18/2018 |
WYY WidePoint | $2.68 +1.1% | 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | High | View details for Dawson James rating of WidePoint (NYSEAMERICAN:WYY) on 12/3/2018 |
WTT Wireless Telecom Group | $2.13
| 12/3/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Wireless Telecom Group (NYSEAMERICAN:WTT) on 12/3/2018 |
CNVS Cineverse | $0.97 -1.0% | 10/22/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Cineverse (NASDAQ:CNVS) on 10/22/2018 |
FRX Fennec Pharmaceuticals | C$9.52 -2.9% | 10/10/2018 | Reiterated by | Dawson James | Analyst C. Werther | Buy | | N/A | View details for Dawson James rating of Fennec Pharmaceuticals (TSE:FRX) on 10/10/2018 |
FENC Fennec Pharmaceuticals | $6.85 -4.2% | 10/11/2018 | Initiated by | Dawson James | Analyst C. Werther | Buy | | High | View details for Dawson James rating of Fennec Pharmaceuticals (NASDAQ:FENC) on 10/11/2018 |
LUNA Luna Innovations | $3.34 +4.4% | 10/2/2018 | Initiated by | Dawson James | Analyst B. Sine | Buy | | Low | View details for Dawson James rating of Luna Innovations (NASDAQ:LUNA) on 10/2/2018 |
SSKN STRATA Skin Sciences | $0.37 -2.6% | 9/4/2018 | Initiated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of STRATA Skin Sciences (NASDAQ:SSKN) on 9/4/2018 |
VERU Veru | $0.97 -3.0% | 6/25/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Medium | View details for Dawson James rating of Veru (NASDAQ:VERU) on 6/25/2018 |
LVO LiveOne | $1.68 -2.3% | 6/4/2018 | Reiterated by | Dawson James | Analyst B. Sine | Buy | | Medium | View details for Dawson James rating of LiveOne (NASDAQ:LVO) on 6/4/2018 |
ALT Altimmune | $7.02 +2.5% | 5/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Altimmune (NASDAQ:ALT) on 5/29/2018 |
ACST Acasti Pharma | $2.70 +3.1% | 1/29/2018 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | Low | View details for Dawson James rating of Acasti Pharma (NASDAQ:ACST) on 1/29/2018 |
CVM CEL-SCI | $1.22 -4.0% | 10/16/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Neutral | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 10/16/2017 |
PAVM PAVmed | $1.44 +0.7% | 9/5/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $151.50 | High | View details for Dawson James rating of PAVmed (NASDAQ:PAVM) on 9/5/2017 |
TNXP Tonix Pharmaceuticals | $0.17
| 8/23/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | $18,000.00 | Medium | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 8/23/2017 |
KTRA Kintara Therapeutics | $0.32 +14.4% | 8/8/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of Kintara Therapeutics (NASDAQ:KTRA) on 8/8/2017 |
EPIX ESSA Pharma | $6.65 +4.4% | 8/3/2017 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | High | View details for Dawson James rating of ESSA Pharma (NASDAQ:EPIX) on 8/3/2017 |
CVM CEL-SCI | $1.22 -4.0% | 3/11/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/11/2016 |
ENZ Enzo Biochem | $1.18 -5.6% | 2/9/2016 | Reiterated by | Dawson James | Analyst R. Wasserman | Buy | | N/A | View details for Dawson James rating of Enzo Biochem (NYSE:ENZ) on 2/9/2016 |
SLNO Soleno Therapeutics | $42.63 -0.6% | 5/6/2015 | Initiated by | Dawson James | - | Buy | $952.50 | N/A | View details for Dawson James rating of Soleno Therapeutics (NASDAQ:SLNO) on 5/6/2015 |
CVM CEL-SCI | $1.22 -4.0% | 3/2/2015 | Initiated by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of CEL-SCI (NYSE:CVM) on 3/2/2015 |
AXGN AxoGen | $7.00 +4.3% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $5.00 | N/A | View details for Dawson James rating of AxoGen (NASDAQ:AXGN) on 5/14/2014 |
NEO NeoGenomics | $14.00 +1.2% | 5/14/2014 | Initiated by | Dawson James | - | Buy | $6.00 | N/A | View details for Dawson James rating of NeoGenomics (NASDAQ:NEO) on 5/14/2014 |
ABIO ARCA biopharma | $3.47 +1.2% | 10/9/2013 | Initiated by | Dawson James | - | Buy | $3.75 | N/A | View details for Dawson James rating of ARCA biopharma (NASDAQ:ABIO) on 10/9/2013 |
AGEN Agenus | $15.11 +0.5% | 3/12/2013 | Reiterated by | Dawson James | - | Buy | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 3/12/2013 |
MD Pediatrix Medical Group | $7.36 +1.4% | 3/12/2013 | Downgraded by | Dawson James | - | Buy -> Neutral | $80.00 | N/A | View details for Dawson James rating of Pediatrix Medical Group (NYSE:MD) on 3/12/2013 |
ARWR Arrowhead Pharmaceuticals | $22.78 -0.4% | 2/26/2013 | Initiated by | Dawson James | - | Buy | $4.00 | N/A | View details for Dawson James rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/26/2013 |
ATOS Atossa Therapeutics | $1.30 -1.5% | 12/20/2012 | Initiated by | Dawson James | - | Outperform | $120.00 | N/A | View details for Dawson James rating of Atossa Therapeutics (NASDAQ:ATOS) on 12/20/2012 |
BMY Bristol-Myers Squibb | $40.25
| 12/12/2012 | Reiterated by | Dawson James | - | Market Outperform | $51.00 | N/A | View details for Dawson James rating of Bristol-Myers Squibb (NYSE:BMY) on 12/12/2012 |
AMGN Amgen | $301.00 +1.6% | 12/7/2012 | Initiated by | Dawson James | - | Outperform | $91.00 | N/A | View details for Dawson James rating of Amgen (NASDAQ:AMGN) on 12/7/2012 |
GEO The GEO Group | $14.14 +3.4% | 12/4/2012 | Downgraded by | Dawson James | - | Market Perform | | N/A | View details for Dawson James rating of The GEO Group (NYSE:GEO) on 12/4/2012 |
SRPT Sarepta Therapeutics | $124.45 +7.1% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Sarepta Therapeutics (NASDAQ:SRPT) on 11/27/2012 |
RMTI Rockwell Medical | $1.77 -1.7% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $132.00 | N/A | View details for Dawson James rating of Rockwell Medical (NASDAQ:RMTI) on 11/27/2012 |
AGEN Agenus | $15.11 +0.5% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Agenus (NASDAQ:AGEN) on 11/27/2012 |
Shocking $16T Elon Musk Crypto Leak (Ad) Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. |
SLS SELLAS Life Sciences Group | $1.40 +3.7% | 11/27/2012 | Initiated by | Dawson James | - | Outperform | $150.00 | N/A | View details for Dawson James rating of SELLAS Life Sciences Group (NASDAQ:SLS) on 11/27/2012 |
CYTK Cytokinetics | $49.12 +2.6% | 11/27/2012 | Downgraded by | Dawson James | - | Outperform | | N/A | View details for Dawson James rating of Cytokinetics (NASDAQ:CYTK) on 11/27/2012 |
GALT Galectin Therapeutics | $2.72 -2.5% | 7/6/2012 | Target Lowered by | Dawson James | - | Buy | $3.00 | N/A | View details for Dawson James rating of Galectin Therapeutics (NASDAQ:GALT) on 7/6/2012 |
TNXP Tonix Pharmaceuticals | $0.17
| 4/26/2012 | Initiated by | Dawson James | - | Buy | $8,000.00 | N/A | View details for Dawson James rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 4/26/2012 |
NFLX Netflix | $647.66 -1.1% | 10/28/2011 | Target Lowered by | Dawson James | - | Sell | $16.50 -> $7.14 | N/A | View details for Dawson James rating of Netflix (NASDAQ:NFLX) on 10/28/2011 |